Research Analysts Set Expectations for TLX FY2025 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Investment analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Telix Pharmaceuticals in a research note issued on Wednesday, January 21st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.09 for the year, down from their previous forecast of $0.19. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. HC Wainwright also issued estimates for Telix Pharmaceuticals’ FY2026 earnings at $0.32 EPS.

Several other analysts also recently issued reports on TLX. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Up 4.2%

NASDAQ:TLX opened at $7.62 on Friday. Telix Pharmaceuticals has a one year low of $7.16 and a one year high of $30.36. The stock has a 50-day simple moving average of $8.48 and a 200 day simple moving average of $10.42.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its stake in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter worth approximately $213,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at $217,000. JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals during the 3rd quarter valued at $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.